Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
We operate primarily on a cash-pay basis to avoid denials, delays, and insurer restrictions
Researchers have also described tissue-protective effects across muscle, bone, and the gastrointestinal tract
Researchers at University of California San Diego School of Medicine have reported results from a large international clinical trial showing that semaglutide, a medication in the GLP-1 class of drugs widely used to treat diabetes and obesity, may help reduce liver scarring in patients with advanced fatty liver disease, including those with early-stage cirrhosis
Sources: Global Glucagon-like Peptide 1 (GLP-1) Market Analysis Report 2023: Potential Clinical Application of GLP-1 Receptor Agonists For the Treatment of NASH Gaining Momentum. GlobeNewswire, January 30, 2023
US$ 24.40
US$ 22.43
US$ 28.17
US$ 28.98
US$ 20.34
US$ 28.79
